Mag-Tab SR Drug Interactions

Serious problems with drug interactions have not been noted with Mag-Tab SR. However, some sources caution about the drug interactions listed in Table 7, which are especially important in patients receiving magnesium sulfate and other magnesium salts administered parenterally. (See Table 7.)

Click on icon to see table/diagram/image

The concurrent use of oral Mg++ salts with sodium polystyrene sulfonate is not recommended since it may bind with oral Mg++ salts.
Excessive intake of ethanol or glucose has been found to increase Mg++ excretion. High intake of ethanol or glucose should be avoided while taking Mg++ salts.
Oral calcium-containing medications may increase serum Ca++ or Mg++ concentrations in susceptible patients, primarily patients with renal insufficiency.
Administration of oral Mg salts with cellulose sodium phosphate or edetate disodium (EDTA) may result in binding of Mg++. Do not administer oral Mg salts within one hour of cellulose sodium phosphate or edetate disodium.
Diuretics may interfere with the kidneys ability to regulate Mg++ levels. Long-term use of PPIs, thiazide or loop diuretics may impair the magnesium-conserving ability of the kidneys and lead to hypomagnesemia.
Concurrent use of Mg++ salts with other magnesium-containing antacids or laxatives may result in magnesium toxicity, especially in patients with renal insufficiency.
Administration of oral Mg++ salts with oral quinolones or tetracycline antibiotics may form nonabsorbable complexes resulting in decreased absorption of the antibiotics. Do not administer oral Mg++ salts within 1 to 3 hours after taking an oral fluoroquinolone or oral tetracycline.
Oral Mg salts may prevent absorption of oral etidronate. Do not administer Mg++ salts within 2 hours of oral etidronate.
Magnesium salts and magnesium-containing antacids should not be used in patients receiving vitamin D analogs. Vitamin D analogs can increase serum Mg++ concentrations in patients with chronic renal failure.